Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Salarius Pharmaceuticals, Inc. (FLKS)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/10/2023 |
8-K
| Quarterly results |
| 11/10/2022 |
8-K
| Quarterly results |
| 08/05/2021 |
8-K
| Quarterly results |
| 05/12/2021 |
8-K
| Quarterly results |
| 05/14/2020 |
8-K
| Quarterly results |
| 05/01/2019 |
8-K
| Quarterly results |
| 03/06/2019 |
8-K
| Quarterly results |
| 11/05/2018 |
8-K
| Quarterly results |
| 08/01/2018 |
8-K
| Quarterly results |
| 05/02/2018 |
8-K
| Quarterly results|
Docs:
|
"Flex Pharma Reports First Quarter 2018 Financial Results -- Positive Anti-Cramping Effect of FLX-787 Reported in Recent MS study -- -- FLX-787 Phase 2 ALS & CMT Clinical Studies Ongoing -- Conference Call Scheduled Today at 9:00 a.m. ET May 2, 2018 Boston, MA - Flex Pharma, Inc. , a clinical-stage biotechnology company that is developing innovative and proprietary treatments in Phase 2 randomized, controlled trials for muscle cramps, spasms and spasticity associated with severe neurological diseases such as multiple sclerosis , amyotrophic lateral sclerosis under FDA Fast Track designation, and Charcot-Marie-Tooth neuropathy, today reported financial results for the quarter ended March 31, 2018 and provided an update on its clinical development and corporate activities. "The past few month..." |
|
| 03/07/2018 |
8-K
| Quarterly results |
| 11/06/2017 |
8-K
| Quarterly results|
Docs:
|
"Flex Pharma Reports Third Quarter 2017 Financial Results -- Recent Positive Topline Data Reported from Exploratory Phase 2 Trial of FLX-787 in ALS -- -- Two US Phase 2b Trials in ALS and CMT Initiated under IND; Data Readouts in 2018 -- -- Development Efforts Expanding into Dysphasia -- Conference Call Scheduled Today at 8:45 a.m. ET November 6, 2017 Boston, MA - Flex Pharma, Inc. , a clinical-stage biotechnology company that is developing innovative and proprietary treatments in Phase 2 randomized, controlled trials for cramps and spasticity associated with severe neurological diseases such as multiple sclerosis , Charcot-Marie-Tooth and amyotrophic lateral sclerosis under FDA Fast Track designation, today reported financial results for the quarter ended September 30, 2017 and provided an...",
"Flex Pharma Reports Positive Topline Data from Exploratory Phase 2 Trial of FLX-787 in ALS -- Statistically Significant Reduction in Cramp-Associated Pain Intensity and Stiffness; Strong and Consistent Trends on Multiple Endpoints Including Anti-Cramp Activity -- -- First Clinical Evidence of Effect for FLX-787 in Neurological Disease -- -- US Phase 2b Trial of FLX-787 for ALS Cramping Ongoing under Fast Track Designation -- Conference Call Scheduled Today at 8:45 a.m. ET Click to Tweet this News November 6, 2017 Boston, MA - Flex Pharma, Inc. , a clinical-stage biotechnology company that is developing innovative and proprietary treatments in Phase 2 randomized, controlled trials for cramps and spasticity associated with severe neurological diseases such as multiple sclerosis , Charcot-Mar...",
"Novel Treatments for Severe Neurological" |
|
| 08/02/2017 |
8-K
| Quarterly results |
| 05/03/2017 |
8-K
| Form 8-K - Current report |
| 03/08/2017 |
8-K
| Form 8-K - Current report |
| 11/02/2016 |
8-K
| Form 8-K - Current report |
| 08/03/2016 |
8-K
| Form 8-K - Current report |
| 05/04/2016 |
8-K
| Form 8-K - Current report |
| 03/08/2016 |
8-K
| Form 8-K - Current report |
| 11/04/2015 |
8-K
| Quarterly results |
| 08/05/2015 |
8-K
| Quarterly results|
Docs:
|
"Flex Pharma Reports Second Quarter 2015 Financial Results Conference Call Scheduled Today at 9:00 a.m. ET August 5, 2015 Boston, MA - Flex Pharma, Inc. , a biotechnology company that is developing innovative and proprietary treatments for exercise-associated muscle cramps, nocturnal leg cramps, and spasms associated with severe neuromuscular conditions, today reported financial results for the quarter ended June 30, 2015, and provided an update on its clinical development and corporate activities. “Based on the novel discovery by our scientific co-founders, we are working to define the impact of chemical neuro-stimulation on reducing cramps and spasms in several important settings. We have made significant progress this quarter in both the development of our clinical candidates as well as ..." |
|
| 05/06/2015 |
8-K
| Quarterly results|
Docs:
|
"Flex Pharma Reports First Quarter 2015 Financial Results Conference Call Scheduled Today at 9:00 a.m. ET May 6, 2015 Boston, MA - Flex Pharma, Inc. , a biotechnology company that is developing innovative and proprietary treatments for exercise-associated muscle cramps, nocturnal leg cramps, and spasms associated with severe neuromuscular conditions, today reported financial results for the quarter ended March 31, 2015, and provided an update on its clinical development and corporate activities. “We were pleased to present our human proof-of-concept data in an oral platform presentation at the recent annual meeting of the American Academy of Neurology as we continue to make clinical progress with the initiation of our studies in nocturnal leg cramps and potentially other settings,” stated C..." |
|
| 03/17/2015 |
8-K
| Quarterly results |
|
|